Radiation boosts targeted therapy in Tough-to-Treat lymphoma
NCT ID NCT06867536
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests whether adding a short course of radiation to the drug glofitamab can help people with a fast-growing type of lymphoma (DLBCL) that has come back or not responded to prior treatment. It focuses on patients with a high tumor burden, who typically do not respond as well to glofitamab alone. About 40 adults aged 18-75 will receive both treatments, and researchers will track how many achieve complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.